Henry Schein, Inc. (NASDAQ:HSIC) Given Average Rating of “Hold” by Brokerages

by · The Cerbat Gem

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been given a consensus rating of “Hold” by the fourteen research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $76.9231.

A number of analysts recently commented on the company. JPMorgan Chase & Co. raised their price target on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Morgan Stanley increased their target price on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Wells Fargo & Company increased their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Barclays began coverage on Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price on the stock. Finally, Barrington Research set a $79.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th.

View Our Latest Research Report on HSIC

Hedge Funds Weigh In On Henry Schein

Hedge funds have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in Henry Schein by 15.9% during the 1st quarter. Wellington Management Group LLP now owns 7,996 shares of the company’s stock valued at $548,000 after purchasing an additional 1,094 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Henry Schein by 1,357.1% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,182 shares of the company’s stock worth $286,000 after purchasing an additional 3,895 shares during the last quarter. Trexquant Investment LP grew its holdings in shares of Henry Schein by 27.3% in the first quarter. Trexquant Investment LP now owns 11,213 shares of the company’s stock valued at $768,000 after purchasing an additional 2,403 shares in the last quarter. State of Wyoming raised its position in Henry Schein by 205.1% during the first quarter. State of Wyoming now owns 11,335 shares of the company’s stock valued at $776,000 after purchasing an additional 7,620 shares during the period. Finally, Magnetar Financial LLC purchased a new stake in shares of Henry Schein in the first quarter valued at $1,809,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Trading Down 1.1%

Shares of HSIC opened at $75.58 on Friday. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The firm has a market cap of $8.90 billion, a price-to-earnings ratio of 23.92, a PEG ratio of 2.34 and a beta of 0.89. The firm has a 50 day moving average price of $72.53 and a 200-day moving average price of $70.08. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40.

Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.11. The company had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, equities research analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

About Henry Schein

(Get Free Report)

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

Featured Stories